Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2010	Feb. 14, 2011	Jun. 30, 2010
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2010
Document Fiscal Year Focus	2010
Document Fiscal Period Focus	FY
Trading Symbol	XRAY
Entity Registrant Name	DENTSPLY INTERNATIONAL INC /DE/
Entity Central Index Key	0000818479
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		142,145,313
Entity Public Float			$ 4,482,457,185

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Net sales	$ 2,221,014	$ 2,159,378	$ 2,191,465
Cost of products sold	1,090,856	1,053,015	1,043,565
Gross profit	1,130,158	1,106,363	1,147,900
Selling, general and administrative expenses	738,901	718,230	735,084
Restructuring and other costs	10,984	6,890	32,355
Operating income	380,273	381,243	380,461
Other income and expenses:
Interest expense	25,089	21,896	32,527
Interest income	(4,254)	(5,032)	(17,089)
Other expense (income), net	1,782	1,023	10,150
Income before income taxes	357,656	363,356	354,873
Provision for income taxes	89,225	88,944	71,603
Equity in net loss of unconsolidated affilated company	(1,096)
Net income	267,335	274,412	283,270
Less: Net income (loss) attributable to noncontrolling interests	1,627	154	(599)
Net income attributable to DENTSPLY International	$ 265,708	$ 274,258	$ 283,869
Earnings per common share:
Basic	$ 1.85	$ 1.85	$ 1.90
Diluted	$ 1.82	$ 1.83	$ 1.87
Weighted average common shares outstanding:
Basic	143,980	148,319	149,069
Diluted	145,985	150,102	151,679

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2009
Current Assets:
Cash and cash equivalents	$ 540,038	$ 450,348
Accounts and notes receivable-trade, net	344,796	348,684
Inventories, net	308,738	291,640
Prepaid expenses and other current assets	121,473	127,124
Total Current Assets	1,315,045	1,217,796
Property, plant and equipment, net	423,105	439,619
Identifiable intangible assets, net	78,743	89,086
Goodwill, net	1,303,055	1,312,596
Other noncurrent assets, net	138,003	28,835
Total Assets	3,257,951	3,087,932
Current Liabilities:
Accounts payable	114,479	100,847
Accrued liabilities	224,745	249,169
Income taxes payable	13,113	12,366
Notes payable and current portion of long-term debt	7,754	82,174
Total Current Liabilities	360,091	444,556
Long-term debt	604,015	387,151
Deferred income taxes	72,489	72,524
Other noncurrent liabilities	311,444	276,743
Total Liabilities	1,348,039	1,180,974
Commitments and contingencies
Equity:
Preferred stock, $.01 par value; .25 million shares authorized; no shares issued
Common stock, $.01 par value; 200.0 million shares authorized; 162.8 million shares issued at December 31, 2010 and December 31, 2009	1,628	1,628
Capital in excess of par value	204,902	195,495
Retained earnings	2,320,350	2,083,459
Accumulated other comprehensive income	24,156	83,542
Treasury stock, at cost, 21.0 million shares at December 31, 2010 and 15.8 million shares at December 31, 2009	(711,650)	(532,019)
Total DENTSPLY International Equity	1,839,386	1,832,105
Noncontrolling Interests	70,526	74,853
Total Equity	1,909,912	1,906,958
Total Liabilities and Equity	$ 3,257,951	$ 3,087,932

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Millions, except Per Share data, unless otherwise specified	Dec. 31, 2010	Dec. 31, 2009
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	0.25	0.25
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200.0	200.0
Common stock, shares issued	162.8	162.8
Treasury stock, shares	21.0	15.8

CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (USD $) In Thousands, unless otherwise specified	Total	Common Stock	Capital in Excess of Par Value	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Total DENTSPLY International Equity	Noncontrolling Interests
Beginning Balance at Dec. 31, 2007	$ 1,516,402	$ 1,628	$ 173,084	$ 1,582,683	$ 145,819	$ (387,108)	$ 1,516,106	$ 296
Purchase of subsidiary shares from noncontrolling interest	71,931							71,931
Comprehensive Income:
Net income	283,270			283,869			283,869	(599)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(71,458)				(71,521)		(71,521)	63
Net loss on derivative financial instruments	(13,986)				(13,986)		(13,986)
Pension liability adjustments	(20,700)				(20,700)		(20,700)
Comprehensive Income	177,126						177,662	(536)
Exercise of stock options	12,726		(7,268)			19,994	12,726
Tax benefit from stock options exercised	3,910		3,910				3,910
Share based compensation expense	17,290		17,290				17,290
Funding of Employee Stock Option Plan	180		62			118	180
Treasury shares purchased	(112,634)					(112,634)	(112,634)
RSU dividends			76	(76)
Cash dividends ($0.200 in 2010,$0.200 in 2009 and $0.185 in 2008 per share)	(27,518)			(27,518)			(27,518)
Ending Balance at Dec. 31, 2008	1,659,413	1,628	187,154	1,838,958	39,612	(479,630)	1,587,722	71,691
Comprehensive Income:
Net income	274,412			274,258			274,258	154
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	53,574				50,566		50,566	3,008
Net loss on derivative financial instruments	(13,960)				(13,960)		(13,960)
Pension liability adjustments	7,324				7,324		7,324
Comprehensive Income	321,350						318,188	3,162
Exercise of stock options	13,406		(11,515)			24,921	13,406
Tax benefit from stock options exercised	3,505		3,505				3,505
Share based compensation expense	16,276		16,276				16,276
Funding of Employee Stock Option Plan	1,345		(63)			1,408	1,345
Treasury shares purchased	(78,718)					(78,718)	(78,718)
RSU dividends			138	(138)
Cash dividends ($0.200 in 2010,$0.200 in 2009 and $0.185 in 2008 per share)	(29,619)			(29,619)			(29,619)
Ending Balance at Dec. 31, 2009	1,906,958	1,628	195,495	2,083,459	83,542	(532,019)	1,832,105	74,853
Comprehensive Income:
Net income	267,335			265,708			265,708	1,627
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(54,111)				(49,519)		(49,519)	(4,592)
Net loss on derivative financial instruments	(12,848)				(12,848)		(12,848)
Net unrealized holding gains on available-for-sale investments	11,029				11,029		11,029
Pension liability adjustments	(8,048)				(8,048)		(8,048)
Comprehensive Income	203,357						206,322	(2,965)
Exercise of stock options	30,189		(10,107)			40,296	30,189
Tax benefit from stock options exercised	4,663		4,663				4,663
Share based compensation expense	18,803		18,803				18,803
Funding of Employee Stock Option Plan	1,340		208			1,132	1,340
Treasury shares purchased	(223,993)					(223,993)	(223,993)
Dividends from noncontrolling interest	(1,362)							(1,362)
RSU distributions	(4,313)		(4,313)				(4,313)
RSU dividends	2,934		153	(153)		2,934	2,934
Cash dividends ($0.200 in 2010,$0.200 in 2009 and $0.185 in 2008 per share)	(28,664)			(28,664)			(28,664)
Ending Balance at Dec. 31, 2010	$ 1,909,912	$ 1,628	$ 204,902	$ 2,320,350	$ 24,156	$ (711,650)	$ 1,839,386	$ 70,526

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Cash flows from operating activities:
Net income	$ 267,335	$ 274,412	$ 283,270
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	56,868	54,087	47,887
Amortization	9,472	11,088	9,042
Deferred income taxes	1,386	195	13,371
Share based compensation expense	18,803	16,276	17,290
Restructuring and other costs - non-cash	379	369	8,303
Stock option income tax benefit	(4,663)	(3,505)	(3,910)
Other non-cash expense (income)	7,249	(8,650)	(19,654)
Loss (gain) on disposal of property, plant and equipment	113	(1,997)	1,373
Changes in operating assets and liabilities, net of acquisitions:
Accounts and notes receivable-trade, net	5,115	(16,942)	(3,690)
Inventories, net	(9,309)	27,710	(32,824)
Prepaid expenses and other current assets	(3,705)	6,996	(1,220)
Other non current assets	(1,154)	(192)	390
Accounts payable	2,165	(4,947)	5,430
Accrued liabilities	9,004	(1,708)	5,748
Income taxes	3,017	8,104	4,594
Other noncurrent liabilities	249	1,193	581
Net cash provided by operating activities	362,324	362,489	335,981
Cash flows from investing activities:
Cash paid for acquisitions of businesses and equity investments	(35,556)	(2,986)	(117,300)
Capital expenditures	(44,236)	(56,481)	(76,440)
Purchase of convertible debt issued by affiliate	(49,654)
Purchase of company owned life insurance policies	(2,000)
Expenditures for identifiable intangible assets	(1,606)	(14)	(2,477)
Purchases of short-term investments			(166,208)
Liquidations of short-term investments		222	314,025
Proceeds from sale of property, plant and equipment	3,562	5,860	596
Net cash used in investing activities	(129,490)	(53,399)	(47,804)
Cash flows from financing activities:
Proceeds from long-term borrowings, net of deferred financing costs	368,611	86,091	117,900
Payments on long-term borrowings	(242,137)	(58,403)	(226,147)
(Decrease) increase in short-term borrowings	(9,657)	(7,465)	2,111
Proceeds from exercise of stock options	30,189	13,406	12,726
Excess tax benefits from share based compensation	4,663	3,505	3,910
Cash paid for treasury stock	(223,993)	(78,718)	(112,634)
Cash dividends paid	(29,077)	(29,836)	(26,952)
Net cash used in financing activities	(101,401)	(71,420)	(229,086)
Effect of exchange rate changes on cash and cash equivalents	(41,743)	8,687	(24,484)
Net increase in cash and cash equivalents	89,690	246,357	34,607
Cash and cash equivalents at beginning of period	450,348	203,991	169,384
Cash and cash equivalents at end of period	540,038	450,348	203,991
Supplemental disclosures of cash flow information:
Interest paid, net of amounts capitalized	21,856	23,231	34,222
Income taxes paid	$ 64,787	$ 76,207	$ 66,696

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2010

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES

Description of Business

DENTSPLY International Inc. (“DENTSPLY” or the “Company”), designs, develops, manufactures and markets a broad range of professional dental products. The Company believes that it is the world's leading manufacturer and distributor of dental prosthetics, endodontic instruments and materials, and ultrasonic scalers; the leading United States manufacturer and distributor of denture teeth, dental handpieces, dental x-ray film holders, film mounts and prophylaxis paste; and a leading worldwide manufacturer or distributor of dental injectable anesthetics, impression materials, orthodontic appliances, dental cutting instruments, dental implants and restorative dental materials, dental sealants, and crown and bridge materials. The Company distributes its dental products in over 120 countries under some of the most well established brand names in the industry.

DENTSPLY is committed to the development of innovative, high quality, cost effective products for the dental market.

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.

Principles of Consolidation

The consolidated financial statements include the accounts of the Company. The Company also consolidates all variable interest entities (“VIE”) where the Company has determined that it has the power to direct the activities that most significantly impact the VIE’s economic performance and shares in either the significant risks or rewards of the VIE. The Company continually reassesses its VIE to determine if consolidation is appropriate. All significant intercompany accounts and transactions are eliminated in consolidation.

Investments in nonconsolidated affiliates (20-50 percent owned companies, joint ventures and partnerships as well as less than 20 percent ownership positions where the Company maintains significant influence over the subsidiary) are accounted for using the equity method.

Cash and Cash Equivalents

Cash and cash equivalents include deposits with banks as well as highly liquid time deposits with maturities at the date of purchase of ninety days or less.

Short-term Investments

Short-term investments are highly liquid time deposits with original maturities at the date of purchase greater than ninety days and with remaining maturities of one year or less.

Accounts and Notes Receivable-Trade

The Company sells dental products through a worldwide network of distributors and directly to end users. For customers on credit terms, the Company performs ongoing credit evaluation of those customers' financial condition and generally does not require collateral from them. The Company establishes allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. The Company records a provision for doubtful accounts, which is included in “Selling, general and administrative expenses.”

Accounts receivable – trade is stated net of these allowances that were $8.8 million and $12.2 million at December 31, 2010 and 2009, respectively. For the years ended December 31, 2010 and 2009, the Company wrote-off $2.6 million and $4.3 million, respectively, of accounts receivable that were previously reserved. The tighter credit markets caused the Company to reassess and tighten its controls over customer credit terms, increase collection efforts and analyze accounts receivable activity. This, along with improved customer liquidity, enabled the Company to reduce the provision for doubtful accounts by $0.2 million and $3.1 million in 2010 and 2009, respectively.

Additionally, notes receivable – trade is stated net of these allowances that were $0.8 million and $1.1 million at December 31, 2010 and 2009, respectively. The Company recorded provisions for doubtful accounts on notes receivable – trade of $0.7 million for 2010 and $0.5 million for 2009. Additionally, the Company wrote-off $1.0 million in 2010.

Inventories

Inventories are stated at the lower of cost or market. At December 31, 2010 and 2009, the cost of $6.9 million, or 2.2%, and $7.8 million, or 2.7%, respectively, of inventories was determined by the last in, first-out (“LIFO”) method. The cost of other inventories was determined by the first-in, first-out (“FIFO”) or average cost methods. The Company establishes reserves for inventory estimated to be obsolete or unmarketable equal to the difference between the cost of inventory and estimated market value based upon assumptions about future demand and market conditions.

If the FIFO method had been used to determine the cost of LIFO inventories, the amounts at which net inventories are stated would be higher than reported at December 31, 2010 and 2009 by $4.9 million and $4.0 million, respectively.

Valuation of Goodwill and Other Long-Lived Assets

Assessment of the potential impairment of goodwill and other long-lived assets is an integral part of the Company’s normal ongoing review of operations. Testing for potential impairment of these assets is significantly dependent on assumptions and reflects management’s best estimates at a particular point in time. The dynamic economic environments in which the Company’s businesses operate and key economic and business assumptions with respect to projected selling prices, increased competition and introductions of new technologies can significantly affect the outcome of impairment tests. Estimates based on these assumptions may differ significantly from actual results. Changes in factors and assumptions used in assessing potential impairments can have a significant impact on the existence and magnitude of impairments, as well as the time at which such impairments are recognized. If there are unfavorable changes in these assumptions, the future cash flows, a key variable in assessing the impairment of these assets, may decrease and as a result the Company may be required to recognize impairment charges. Future changes in the environment and the economic outlook for the assets being evaluated could also result in additional impairment charges being recognized. The following information outlines the Company’s significant accounting policies on long-lived assets by type.

Goodwill

US GAAP requires that at least an annual impairment test be applied to goodwill. The Company performs impairment tests using a fair value approach. If impairment is identified on goodwill, the resulting charge is determined by recalculating goodwill through a hypothetical purchase price allocation of the fair value and reducing the current carrying value to the extent it exceeds the recalculated goodwill.

The Company’s fair value approach involves using a discounted cash flow model with market-based support as its valuation technique to measure the fair value for its reporting units. The discounted cash flow model uses five year forecasted cash flows plus a terminal value based on a multiple of earnings. In addition, the Company applies gross profit and operating expense assumptions consistent with its historical trends. The total cash flows were discounted based on market participant data, which included the Company’s weighted-average cost of capital. The Company considered the current market conditions when determining its assumptions. Lastly, the Company reconciled the aggregate fair values of its reporting units to its market capitalization, which included a reasonable control premium based on market conditions. Additional information related to the testing for goodwill impairment is provided in Note 8, Goodwill and Intangible Assets.

Identifiable Definite-Lived Intangible Assets

Identifiable definite-lived intangible assets, which primarily consist of patents, trademarks, brand names, non-compete agreements and licensing agreements, are amortized on a straight-line basis over their estimated useful lives. These assets are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset may not be recoverable. The Company closely monitors certain intangible assets related to new and existing technologies for indicators of impairment as these assets have more risk of becoming impaired. Impairment is based upon an initial evaluation of the identifiable undiscounted cash flows. If the initial evaluation identifies a potential impairment, a fair value is determined by using a discounted cash flows valuation. If impaired, the resulting charge reflects the excess of the asset’s carrying cost over its fair value.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, net of accumulated depreciation. Except for leasehold improvements, depreciation for financial reporting purposes is computed by the straight-line method over the following estimated useful lives: buildings - generally 40 years and machinery and equipment - 4 to 15 years. The cost of leasehold improvements is amortized over the shorter of the estimated useful life or the term of the lease. Maintenance and repairs are expensed as incurred to the statement of operations; replacements and major improvements are capitalized. These assets groups are reviewed for impairment whenever events or circumstances suggest that the carrying amount of the asset group may not be recoverable. Impairment is based upon an evaluation of the identifiable undiscounted cash flows. If impaired, the resulting charge reflects the excess of the asset group’s carrying cost over its fair value.

Marketable Security

The Company’s marketable securities consist of debt instruments that are classified as available-for-sale in “Other noncurrent assets” on the consolidated balance sheets as the instruments mature in December 2015. The Company determined the appropriate classification at the time of purchase and will re-evaluate such designation as of each balance sheet date. In addition, the Company reviews the securities each quarter for indications of possible impairment. Once impairment is identified, the determination of whether the impairment is temporary or other-than-temporary requires significant judgment. The primary factors that the Company considers in classifying the impairment include the extent and time the fair value of each investment has been below cost and the existence of a credit loss. If a decline in fair value is judged other-than-temporary, the basis of the securities is written down to fair value and the amount of the write-down is included as a realized loss.

Derivative Financial Instruments

The Company requires that all derivative instruments be recorded on the balance sheet at fair value and that changes in fair value be recorded each period in current earnings or accumulated other comprehensive income (“AOCI”).

The Company employs derivative financial instruments to hedge certain anticipated transactions, firm commitments, and assets and liabilities denominated in foreign currencies. Additionally, the Company utilizes interest rate swaps to convert floating rate debt to fixed rate, fixed rate debt to floating rate, cross currency basis swaps to convert debt denominated in one currency to another currency, and commodity swaps to fix its variable raw materials costs.

Pension and Other Postretirement Benefits

Substantially all of the employees of the Company and its subsidiaries are covered by government or Company-sponsored defined benefit or defined contribution plans. Additionally, certain union and salaried employee groups in the United States are covered by postretirement healthcare plans. Costs for Company-sponsored plans are based on expected return on plan assets, discount rates, employee compensation increase rates and health care cost trends. Expected return on plan assets, discount rates and health care cost trend assumptions are particularly important when determining the Company’s benefit obligations and net periodic benefit costs associated with postretirement benefits. Changes in these assumptions can impact the Company’s earnings before income taxes. In determining the cost of postretirement benefits, certain assumptions are established annually to reflect market conditions and plan experience to appropriately reflect the expected costs as actuarially determined. These assumptions include medical inflation trend rates, discount rates, employee turnover and mortality rates. The Company predominantly uses liability durations in establishing its discount rates, which are observed from indices of high-grade corporate bond yields in the respective economic regions of the plans. The expected return on plan assets is the weighted average long-term expected return based upon asset allocations and historic average returns for the markets where the assets are invested, principally in foreign locations. The Company reports the funded status of its defined benefit pension and other postretirement benefit plans on its consolidated balance sheets as a net liability or asset. Additional information related to the impact of changes in these assumptions is provided in Note 13, Benefit Plans.

Accruals for Self-Insured Losses

The Company maintains insurance for certain risks, including workers’ compensation, general liability, product liability and vehicle liability, and is self-insured for employee related health care benefits. The Company accrues for the expected costs associated with these risks by considering historical claims experience, demographic factors, severity factors and other relevant information. Costs are recognized in the period the claim is incurred, and the financial statement accruals include an estimate of claims incurred but not yet reported. The Company has stop-loss coverage to limit its exposure to any significant exposure on a per claim basis.

Litigation

The Company and its subsidiaries are from time to time parties to lawsuits arising out of their respective operations. The Company records liabilities when a loss is probable and can be reasonably estimated. These estimates are typically in the form of ranges, and the Company records the liabilities at the low point of the ranges. The ranges established by management are based on an analysis made by internal and external legal counsel who considers information known at the time. If the Company determines a liability to be only reasonably possible, it considers the same information to estimate the possible exposure and disclose any material potential liability. These loss contingencies are monitored regularly for a change in fact or circumstance that would require an accrual adjustment. The Company believes it has estimated liabilities for probable losses well in the past; however, the unpredictability of litigation and court decisions could cause a liability to be incurred in excess of estimates. Legal costs related to these lawsuits are expensed as incurred.

Accumulated Other Comprehensive Income

AOCI includes foreign currency translation adjustments related to the Company’s foreign subsidiaries, net of the related changes in certain financial instruments hedging these foreign currency investments. In addition, changes in the Company’s fair value of certain derivative financial instruments, net unrealized holding gain on available-for-sale securities and pension liability adjustments and prior service costs, net are recorded in AOCI. These changes are recorded in AOCI net of any related tax adjustments. For the years ended December 31, 2010, 2009 and 2008, these tax adjustments were $158.7 million, $143.0 million and $138.5 million, respectively, primarily related to foreign currency translation adjustments.

The balances included in AOCI in the consolidated balance sheets are as follows:

	December 31,
(in thousands)	2010			2009

Foreign currency translation adjustments	$	170,597		$	220,116
Net loss on derivative financial instruments		(126,648	)		(113,800	)
Net unrealized holding gain on available for-sale securities		11,029			-
Pension liability adjustments		(30,822	)		(22,774	)
	$	24,156		$	83,542

The cumulative foreign currency translation adjustments included translation gains of $294.6 million and $327.8 million as of December 31, 2010 and 2009, respectively, offset by losses of $124.0 million and $107.7 million, respectively, on loans designated as hedges of net investments.

Foreign Currency Translation

The functional currency for foreign operations, except for those in highly inflationary economies, has been determined to be the local currency.

Assets and liabilities of foreign subsidiaries are translated at foreign exchange rates on the balance sheet date; revenue and expenses are translated at the average year-to-date foreign exchange rates. The effects of these translation adjustments are reported in Equity within AOCI of the consolidated balance sheets. During the year ended December 31, 2010, the Company had losses of $16.3 million on its loans designated as hedges of net investments and translation losses of $33.2 million. During the year ended December 31, 2009, the Company had gains of $0.9 million on its loans designated as hedges of net investments and translation gains of $49.7 million.

Foreign exchange gains and losses arising from transactions denominated in a currency other than the functional currency of the entity involved and remeasurement adjustments in countries with highly inflationary economies are included in income. Net foreign exchange losses of $3.3 million, net foreign exchange gains of $0.3 million and net foreign exchange losses of $8.9 million in 2010, 2009, and 2008, respectively, are included in “Other expense (income), net.”

Revenue Recognition

Revenue, net of related discounts and allowances, is recognized when the earnings process is complete. This occurs when products are shipped to or received by the customer in accordance with the terms of the agreement, title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Net sales include shipping and handling costs collected from customers in connection with the sale. Sales taxes, value added taxes and other similar types of taxes collected from customers in connection with the sale are recorded by the Company on a net basis and are not included in the statement of operations.

Certain of the Company’s customers are offered cash rebates based on targeted sales increases. In accounting for these rebate programs, the Company records an accrual as a reduction of net sales for the estimated rebate as sales take place throughout the year.

A portion of the Company’s net sales is comprised of sales of precious metals generated through its precious metal dental alloy product offerings. As the precious metal content of the Company’s sales is largely a pass-through to customers, the Company uses its cost of precious metal purchased as a proxy for the precious metal content of sales, as the precious metal content of sales is not separately tracked and invoiced to customers. The Company believes that it is reasonable to use the cost of precious metal content purchased in this manner since precious metal alloy sale prices are typically adjusted when the prices of underlying precious metals change. The precious metals content of sales was $189.2 million, $168.7 million and $200.0 million for 2010, 2009 and 2008, respectively.

Cost of Products Sold

Cost of products sold represents costs directly related to the manufacture and distribution of the Company’s products. Primary costs include raw materials, packaging, direct labor, overhead, shipping and handling, warehousing and the depreciation of manufacturing, warehousing and distribution facilities. Overhead and related expenses include salaries, wages, employee benefits, utilities, lease costs, maintenance and property taxes.

Warranties

The Company provides warranties on certain equipment products. Estimated warranty costs are accrued when sales are made to customers. Estimates for warranty costs are based primarily on historical warranty claim experience. Warranty costs are included in “Cost of products sold.”

Selling, General and Administrative Expenses

Selling, general and administrative expenses represent costs incurred in generating revenues and in managing the business of the Company. Such costs include advertising and other marketing expenses, salaries, employee benefits, incentive compensation, research and development, travel, office expenses, lease costs, amortization of capitalized software and depreciation of administrative facilities.

Research and Development Costs

Research and development (“R&D”) costs relate primarily to internal costs for salaries and direct overhead expenses. In addition, the Company contracts with outside vendors to conduct R&D activities. All such R&D costs are charged to expense when incurred. The Company capitalizes the costs of equipment that have general R&D uses and expenses such equipment that is solely for specific R&D projects. The depreciation expense related to this capitalized equipment is included in the Company’s R&D costs. R&D costs are included in “Selling, general and administrative expenses” and amounted to $49.4 million, $50.3 million and $48.5 million for 2010, 2009 and 2008, respectively. The year-over-year comparisons for 2010 versus 2009 and 2009 versus 2008 were both impacted by foreign currency translation which decreased the reported expense variations.

Stock Compensation

The Company recognizes the compensation cost relating to share-based payment transactions in the financial statements. The cost of share-based payment transactions is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the employee’s requisite service period (generally the vesting period of the equity awards). The compensation cost is only recognized for the portion of the awards that are expected to vest.

Income Taxes

The Company’s tax expense includes U.S. and international income taxes plus the provision for U.S. taxes on undistributed earnings of international subsidiaries not deemed to be permanently invested. Tax credits and other incentives reduce tax expense in the year the credits are claimed. Certain items of income and expense are not reported in tax returns and financial statements in the same year. The tax effect of such temporary differences is reported as deferred income taxes. Deferred tax assets are recognized if it is more likely than not that the assets will be realized in future years. The Company establishes a valuation allowance for deferred tax assets for which realization is not likely.

The Company applies a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The Company recognizes in the financial statements, the impact of a tax position, if that position is more likely than not of being sustained on audit, based on the technical merits of the position.

Earnings Per Share

Basic earnings per share are calculated by dividing net earnings by the weighted average number of shares outstanding for the period. Diluted earnings per share is calculated by dividing net earnings by the weighted average number of shares outstanding for the period, adjusted for the effect of an assumed exercise of all dilutive options outstanding at the end of the period.

Business Acquisitions

The Company acquires businesses as well as partial interests in businesses. Acquired businesses are accounted for using the acquisition method of accounting which requires that the purchase price be allocated to net assets at their respective fair values. Any excess of the purchase price over estimated fair values of net assets is recorded as goodwill. Under the acquisition method, amounts allocated to acquired in-process research and development and contingent consideration are recorded to the consolidated balance sheet at the date of acquisition at their respective fair values. The assumptions made in determining fair value assigned to acquired assets and liabilities as well as asset lives can materially impact the results of operations.

The Company obtains information during due diligence and through other sources to get respective fair values. Examples of factors and information that the Company uses to determine the fair values include: tangible and intangible asset evaluations and appraisals; evaluations of existing contingencies and liabilities; product line integration information; and information systems compatibilities. If the initial accounting for an acquisition is incomplete by the end of the quarter in which the acquisition occurred, the Company will record a provisional estimate in the financial statements. The provisional estimate will be finalized as soon as information becomes available but will only occur up to one year from the acquisition date.

Equity Method Investments

Investments in partnerships, joint ventures and less-than-majority-owned subsidiaries in which the Company has significant influence are accounted for under the equity method.

Equity investments are carried at original cost adjusted for the proportionate share of the investees’ income, losses and distributions. The Company assesses the carrying value of its equity investments when an indicator of a loss in value is present and record a loss in value of the investment when the assessment indicates that an other-than-temporary decline in the investment exists.

The Company classifies its equity in net earnings of unconsolidated affiliates in the consolidated statements of operations under the title of “Equity in net loss of unconsolidated affiliated company”.

Noncontrolling Interests

The Company reports noncontrolling interest (“NCI”) in a subsidiary as a separate component of Equity in the consolidated balance sheets. Additionally, the Company reports the portion of net income and comprehensive income (loss) attributed to the Company and NCI separately in the consolidated statements of operations. The Company also includes a separate column for NCI in the consolidated statements of changes in equity and comprehensive income.

Variable Interest Entities

On January 1, 2010, the Company adopted the new accounting guidance for variable interest entities (“VIE”). The guidance includes: (1) the elimination of the exemption from consolidation for qualifying special purpose entities, (2) a new approach for determining the primary beneficiary of a VIE, which requires that the primary beneficiary have both (i) the power to control the most significant activities of the VIE and (ii) either the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE, and (3) the requirement to continually reassess who should consolidate a VIE. The adoption did not have a material impact on the Company’s financial position and results of operations.

The Company consolidates all VIE where the Company has determined that it has the power to direct the activities that most significantly impact the VIE’s economic performance and shares in either the significant risks or rewards of the VIE. The Company continually reassesses VIE to determine if consolidation is appropriate. The Company continues to believe that it is the primary beneficiary of Materialise Dental N.V. (“Materialise”) and Zhermack S.p.A. (“Zhermack”) under this new accounting guidance for VIE. The accounting for Materialise and Zhermack are discussed further in Note 3, Business Acquisitions.

Segment Reporting

The Company has numerous operating businesses covering a wide range of products and geographic regions, primarily serving the professional dental market. Professional dental products represented approximately 97% of sales in 2010, 2009 and 2008. The Company has four reportable segments and a description of the activities of these segments is included in Note 4, Segment and Geographic Information.

Fair Value Measurement

Recurring Basis

The Company records certain financial assets and liabilities at fair value in accordance with the accounting guidance, which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The accounting guidance establishes a hierarchal disclosure framework associated with the level of pricing observability utilized in measuring financial instruments at fair value. The three broad levels defined by the fair value hierarchy are as follows:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reported date.

Level 2 – Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reported date. The nature of these financial instruments include, derivative instruments whose fair value have been derived using a model where inputs to the model are directly observable in the market, or can be derived principally from or corroborated by observable market data.

Level 3 – Instruments that have little to no pricing observability as of the reported date. These financial instruments do not have two-way markets and are measured using management’s best estimate of fair value, where the inputs into the determination of fair value require significant management judgment or estimation.

The degree of judgment utilized in measuring the fair value of certain financial assets and liabilities generally correlates to the level of pricing observability. Pricing observability is impacted by a number of factors, including the type of financial instrument. Financial assets and liabilities with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of pricing observability and a lesser degree of judgment utilized in measuring fair value. Conversely, financial assets and liabilities rarely traded or not quoted will generally have less, or no pricing observability and a higher degree of judgment utilized in measuring fair value.

The Company primarily applies the market approach for recurring fair value measurements and endeavors to utilize the best available information. Accordingly, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Additionally, the Company considers its credit risks and its counterparties' credit risks when determining the fair values of its financial assets and liabilities. The Company has presented the required disclosures in Note 16, Fair Value Measurement.

Non-Recurring Basis

When events or circumstances require an asset or liability to be fair valued that otherwise is generally recorded based on another valuation method, such as, net realizable value, the Company will utilize the valuation techniques described above.

Reclassification of Prior Year Amounts

Certain reclassifications have been made to prior years' data in order to conform to current year presentation.

EARNINGS PER COMMON SHARE

12 Months Ended

Dec. 31, 2010

EARNINGS PER COMMON SHARE

NOTE 2 - EARNINGS PER COMMON SHARE

The following table sets forth the computation of basic and diluted earnings per common share:

	Net income
	attributable to
	DENTSPLY				Earnings per
(in thousands, except for share amounts)	International		Shares		common share
Year Ended December 31, 2010
Basic	$	265,708		143,980	$	1.85
Incremental shares from assumed exercise of dilutive options		-		2,005

Diluted	$	265,708		145,985	$	1.82

Year Ended December 31, 2009
Basic	$	274,258		148,319	$	1.85
Incremental shares from assumed exercise of dilutive options		-		1,783

Diluted	$	274,258		150,102	$	1.83

Year Ended December 31, 2008
Basic	$	283,869		149,069	$	1.90
Incremental shares from assumed exercise of dilutive options		-		2,610

Diluted	$	283,869		151,679	$	1.87

Options to purchase 3.1 million, 2.9 million and 1.6 million shares of common stock that were outstanding during the years ended 2010, 2009 and 2008, respectively, were not included in the computation of diluted earnings per common share since the options' exercise prices were greater than the average market price of the common shares and, therefore, the effect would be antidilutive.

BUSINESS ACQUISITIONS AND INVESTMENTS IN AFFILIATES

12 Months Ended

Dec. 31, 2010

BUSINESS ACQUISITIONS AND INVESTMENTS IN AFFILIATES

NOTE 3 - BUSINESS ACQUISITIONS AND INVESTMENTS IN AFFILIATES

During 2010, the acquisition related activity was $35.6 million, net of cash acquired, which included a payment for a non-controlling interest investment in DIO Corporation (“DIO”). In 2009, the acquisition related activity was $3.0 million, net of cash. This activity was related to an additional earn-out payment on a prior acquisition from 2007 and the acquisition of a small sales and marketing organization of 3D digital implantology products.

Investment in Affiliates

On December 9, 2010, the Company purchased an initial ownership interest of 16% of the outstanding shares of DIO. The Company accounts for the ownership in DIO under the equity method of accounting as it has significant influence over DIO. In addition, on December 9, 2010, the Company invested $49.7 million in the corporate convertible bonds of DIO, which may be converted into commons shares after a one year period. The bonds are designated by the Company as available-for-sale securities which are reported in, “Other noncurrent assets, net,” on the consolidated balance sheets and the changes in fair value are reported in AOCI. The convertible feature of the bond has not been bifurcated from the underlying bond as the feature does not contain a net-settlement feature, nor would the Company be able to achieve a hypothetical net-settlement that would substantially place the Company in a comparable cash settlement position. As such, the derivative is not accounted for separately from the bond. The cash paid by the Company is equal to the face value of the bonds issued by DIO, and therefore, the Company has not recorded any bond premium or discount on acquiring the bonds. At December 31, 2010, the amortized cost and fair value of the DIO bond was $49.7 million and $66.0 million, respectively, and $11.0 million of unrealized holding gains on available-for-sale securities, net of tax, have been recorded in AOCI. The contractual maturity of the bond is in December 2015.

DIO is located in Busan, South Korea and manufactures a wide range of dental implants including STEADY®, BioTite-H, SM implant, internal implant, external implant, ProTem implant, and SM Extra Wide implant systems. In addition, DIO offers various dental devices including implant surgical devices, handpieces, dental materials, impression materials sterilizers, toothpaste that contains dyrdoxyapatite, and the iTero® 3D intra-oral scanner (Cadent Inc.).

Business Acquisitions

The business acquisitions were related to the purchase of several small distributors that sell dental specialty products. The purchase agreements for three of the acquisitions provide for additional payments to be made based upon the achievement of certain operating performance of the respective businesses; however, the Company does not expect the additional payments to be material to the financial statements. The results of operations for these businesses have been included in the accompanying financial statements since the effective date of the respective transactions. The purchase prices have been allocated on the basis of preliminary estimates of the fair values of assets acquired and liabilities assumed.

Variable Interest Entities

The Company adopted new accounting guidance for VIE on January 1, 2010, which is discussed in Note 1, Significant Accounting Policies. The Company continues to believe that it will be the primary beneficiary of Materialise and Zhermack under this accounting guidance for VIE.

Additional Earn-out Payments

Several of the Company’s 2005, 2007 and 2008 acquisitions included provisions for possible additional payments based on the future performance of the individual businesses (generally for two to three years). During 2010, the Company paid $5.1 million in additional purchase price under these agreements.

Fair Value Allocations for the Business Acquisitions and Additional Earnout Payments

As of December 31, 2010, the Company has recorded a total of $20.4 million in goodwill related to four business combinations, one investment in an unconsolidated affiliate, and additional earn-out payments on acquisitions from prior years. None of this goodwill is expected to be deductible for tax purposes.

The following table summarizes the estimated fair values of the indentified assets acquired and liabilities assumed (in thousands):

Current assets	$	10,755
Property, plant and equipment		1,255
Identifiable intangible assets and goodwill		21,055
Other long-term assets		28
Total assets	$	33,093
Current liabilities		(12,495	)
Long-term liabilities		(1,283	)
Total liabilities	$	(13,778	)
Net assets	$	19,315

Also, as a result of the finalization of fair values assigned to assets acquired and liabilities assumed from 2010 acquisition related activity, the Company has recorded a total of $0.7 million in intangible assets as non-compete agreements and customer lists with an average weighted life of 5.0 years.

Goodwill was assigned to the following four segments:

•	$1.5 million to U.S., Germany, and Certain Other European Regions Consumable Businesses;

•	$12.7 million Canada/Latin America/Endodontics/Orthodontics; and,

•	$6.2 million to Dental Laboratory Business/Implants/Non-Dental.

SEGMENT AND GEOGRAPHIC INFORMATION

12 Months Ended

Dec. 31, 2010

SEGMENT AND GEOGRAPHIC INFORMATION

NOTE 4 – SEGMENT AND GEOGRAPHIC INFORMATION

The operating businesses are combined into operating groups, which have overlapping product offerings, geographical presence, customer bases, distribution channels and regulatory oversight. These operating groups are considered the Company’s reportable segments as the Company’s chief operating decision-maker regularly reviews financial results at the operating group level and uses this information to manage the Company’s operations. The accounting policies of the segments are consistent with those described for the consolidated financial statements in the summary of significant accounting policies (see Note 1, Significant Accounting Policies). The Company measures segment income for reporting purposes as net operating income before restructuring, impairments, and other costs, interest and taxes. Additionally, net operating income is derived from net third party sales, excluding precious metal content. A description of the services provided within each of the Company’s four reportable segments is provided below. The disclosure below reflects the Company’s segment reporting structure.

In January 2010, the Company moved the reporting responsibility for several locations between segments as a result of a change to the management structure. This change also helped the Company gain operating efficiencies and effectiveness. The segment information below reflects this revised structure for all periods shown.

United States, Germany and Certain Other European Regions Consumable Businesses

This business group includes responsibility for the design, manufacturing, sales and distribution of certain small equipment and chairside consumable products in the United States, Germany and certain other European regions. It also has responsibility for the sales and distribution of certain Endodontic products in Germany.

France, United Kingdom, Italy and Certain Other European Countries, CIS, Middle East, Africa, Pacific Rim Businesses

This business group includes responsibility for the sales and distribution for certain small equipment, chairside consumable products, certain laboratory products and certain Endodontic products in France, United Kingdom, Italy, the Commonwealth of Independent States (“CIS”), Middle East, Africa, Asia (excluding Japan), Japan and Australia, as well as the sale and distribution of implant products and bone substitute/grafting materials in France, Italy, Asia and Australia. This business group also includes the responsibility for sales and distribution for certain laboratory products, implants products and bone substitution/grafting materials for Austria. It also is responsible for sales and distribution of certain small equipment and chairside consumable products, certain laboratory products, implant products and bone substation/grafting materials in certain other European countries. In addition this business group also includes the manufacturing and sale of Orthodontic products and certain laboratory products in Japan, and the manufacturing of certain laboratory and certain Endodontic products in Asia.

Canada/Latin America/Endodontics/Orthodontics

This business group includes responsibility for the design, manufacture, and/or sales and distribution of certain small equipment, chairside consumable products, certain laboratory products and Endodontic products in Brazil. It also has responsibility for the sales and distribution of most of the Company’s dental products sold in Latin America and Canada. This business group also includes the responsibility for the design and manufacturing of Endodontic products in the United States, Switzerland and Germany and is responsible for the sales and distribution of the Company’s Endodontic products in the United States, Canada, Switzerland, Benelux, Scandinavia, Austria, Latin America and Eastern Europe, and for certain Endodontic products in Germany. This business group is also responsible for the world-wide sales and distribution, excluding Japan, as well as some manufacturing of the Company’s Orthodontic products. In addition, this business group is also responsible for sales and distribution in the United States of implant and bone substitute/grafting materials and the sales and distribution of implants in Brazil. This business group is also responsible for the manufacture and sale of certain products in the Company’s non-dental business.

Dental Laboratory Business/Implants/Non-Dental

This business group includes the responsibility for the design, manufacture, sales and distribution of most laboratory products, excluding certain countries mentioned previously, and the design, manufacture, and/or sales and distribution of the Company’s dental implant products and bone substitute/grafting materials, excluding sales and distribution of implants and bone substitute/grafting materials in the United States; France, Italy, Austria, and certain other Eastern European countries; and Australia. This business group is also responsible for most of the Company’s non-dental business.

Significant interdependencies exist among the Company’s operations in certain geographic areas. Inter-group sales are at prices intended to provide a reasonable profit to the manufacturing unit after recovery of all manufacturing costs and to provide a reasonable profit for purchasing locations after coverage of marketing, sales, distribution and general and administrative costs.

Generally, the Company evaluates performance of the operating groups based on the groups’ operating income, excluding restructuring, impairments and other costs, interest and taxes, and net third party sales, excluding precious metal content. The Company considers net third party sales, excluding precious metal content, as the appropriate sales measurement due to the fluctuations of precious metal prices and due to the fact that the precious metal content is largely a pass-through to customers and has a minimal effect on earnings.

The following table sets forth information about the Company’s operating groups for the years ended December 31, 2010, 2009 and 2008.

Third Party Net Sales

(in thousands)	2010			2009			2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	526,781		$	526,668		$	459,678

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		482,146			471,232			487,126

Canada/Latin America/Endodontics/
Orthodontics		665,032			621,256			632,151

Dental Laboratory Business/
Implants/Non-Dental		550,359			543,637			618,077

All Other (a)		(3,304	)		(3,415	)		(5,567	)
Total net sales	$	2,221,014		$	2,159,378		$	2,191,465

(a)

Includes amounts recorded at Corporate headquarters.

Third Party Net Sales, Excluding Precious Metal Content

(in thousands)	2010			2009			2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	526,781		$	526,668		$	459,678

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		445,627			436,790			456,192

Canada/Latin America/Endodontics/
Orthodontics		662,556			618,414			628,887

Dental Laboratory Business/
Implants/Non-Dental		400,097			412,209			452,352

All Other (b)		(3,304	)		(3,415	)		(5,567	)
Total net sales, excluding precious metal content	$	2,031,757		$	1,990,666		$	1,991,542
Precious metal content of sales		189,257			168,712			199,923
Total net sales, including precious metal content	$	2,221,014		$	2,159,378		$	2,191,465

(b)

Includes results of Corporate headquarters and one distribution warehouse not managed by named segments.

Intersegment Net Sales

(in thousands)	2010			2009			2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	116,440		$	104,328		$	130,463

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		17,103			13,202			15,941

Canada/Latin America/Endodontics/
Orthodontics		115,158			103,329			106,031

Dental Laboratory Business/
Implants/Non-Dental		112,285			114,591			123,157

All Other (c)		179,780			176,539			177,251
Eliminations		(540,766	)		(511,989	)		(552,843	)
Total	$	-		$	-		$	-

(c)

Includes amounts recorded at Corporate headquarters.

Depreciation and Amortization

(in thousands)	2010		2009		2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	16,315	$	14,945	$	12,807

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		3,939		3,884		3,188

Canada/Latin America/Endodontics/
Orthodontics		18,419		16,978		17,179

Dental Laboratory Business/
Implants/Non-Dental		20,479		21,461		16,062

All Other (d)		7,188		7,907		7,693
Total	$	66,340	$	65,175	$	56,929

(d)

Includes amounts recorded at Corporate headquarters.

Segment Operating Income

(in thousands)	2010			2009			2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	176,128		$	158,389		$	162,717

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		17,187			19,737			14,474

Canada/Latin America/Endodontics/
Orthodontics		195,817			185,772			200,101

Dental Laboratory Business/
Implants/Non-Dental		83,428			92,554			123,442

All Other (e)		(81,303	)		(68,319	)		(87,918	)
Segment Operating Income	$	391,257		$	388,133		$	412,816

Reconciling Items:
Restructuring and other costs		10,984			6,890			32,355
Interest expense		25,089			21,896			32,527
Interest income		(4,254	)		(5,032	)		(17,089	)
Other expense (income), net		1,782			1,023			10,150
Income before income taxes	$	357,656		$	363,356		$	354,873

(e)

Includes results of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

Capital Expenditures

(in thousands)	2010		2009		2008

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	9,267	$	8,333	$	19,836

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		2,978		2,506		3,839

Canada/Latin America/Endodontics/
Orthodontics		17,078		14,434		19,593

Dental Laboratory Business/
Implants/Non-Dental		11,397		25,546		24,510

All Other (f)		3,516		5,662		8,662
Total	$	44,236	$	56,481	$	76,440

(f)

Includes capital expenditures of Corporate headquarters.

Assets

(in thousands)	2010		2009

U.S., Germany and Certain Other
European Regions Consumable Businesses	$	578,770	$	602,272

France, U.K., Italy and Certain Other
European Countries, CIS, Middle East,
Africa, Pacific Rim Businesses		390,572		388,831

Canada/Latin America/Endodontics/
Orthodontics		932,126		809,924

Dental Laboratory Business/
Implants/Non-Dental		995,090		973,764

All Other (g)		361,393		313,141
Total	$	3,257,951	$	3,087,932

(g)

Includes assets of Corporate headquarters, inter-segment eliminations and one distribution warehouse not managed by named segments.

Geographic Information

The following table sets forth information about the Company's operations in different geographic areas for the years ended December 31, 2010, 2009 and 2008. Net sales reported below represent revenues for shipments made by operating businesses located in the country or territory identified, including export sales. Assets reported represent those held by the operating businesses located in the respective geographic areas.

	United				Other
(in thousands)	States		Germany		Foreign		Consolidated

2010
Net sales	$	841,232	$	469,796	$	909,986	$	2,221,014
Long-lived assets		119,533		116,916		186,656		423,105

2009
Net sales	$	843,349	$	482,130	$	833,899	$	2,159,378
Long-lived assets		124,129		132,348		183,143		439,620

2008
Net sales	$	865,743	$

CONSOLIDATED STATEMENTS OF EQUITY AND COMPREHENSIVE INCOME (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Cash dividends, per share	$ 0.200	$ 0.200	$ 0.185